Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.

In patients with non-alcoholic fatty liver disease (NAFLD), insulin resistance (IR) associates with fibrosis progression independently of the hepatic inflammation, but the mechanisms are still unclear. We modeled the independent contribution of inflammation (non-alcoholic steatohepatitis: NASH) by exploiting the methionine-choline deficient (MCD) diet, and that of IR by insulin receptor (InsR) haploinsufficiency (InsR+/-) in the pathogenesis of liver fibrosis in C57BL/6 mice. We confirmed the study findings in 96 patients with NAFLD. InsR+/- enhanced hepatic fat content and impaired hepatic insulin signaling leading to Forkhead box protein O1 (FoxO1) accumulation in MCD-fed mice. Remarkably, despite reduced inflammation and hampered transdifferentiation of hepatic stellate cells (HSCs), InsR+/- promoted hepatic fibrosis accumulation, which correlated with the induction of the Lysyl Oxidase Like 2 (Loxl2), involved in matrix stabilization. Loxl2 up-regulation was not a cell autonomous property of insulin resistant HSCs, but was dependent on microparticles (MPs) released specifically by insulin resistant hepatocytes (HEPs) exposed to fatty acids. The mechanism entailed FoxO1 up-regulation, as FoxO1 silencing normalized Loxl2 expression reversing fibrosis in InsR+/- MCD-fed mice. Loxl2 up-regulation was similarly detected during IR induced by obesity, but not by lipogenic stimuli (fructose feeding). Most importantly, LOXL2 up-regulation was observed in NAFLD patients with type 2 diabetes (T2D) and LOXL2 hepatic and circulating levels correlated with histological fibrosis progression. IR favors fibrosis deposition independently of the classic 'inflammation - HSC transdifferentiation' pathway. The mechanism entails a cross-talk between enhanced lipotoxicity in insulin resistant HEPs and Loxl2 production by HSCs, which was confirmed in patients with diabetes, thereby facilitating extracellular matrix (ECM) stabilization.

[1]  E. Paschetta,et al.  Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis , 2017, JAMA internal medicine.

[2]  G. Marchesini,et al.  AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[3]  J. Trebicka,et al.  Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression , 2017, Gut.

[4]  D. Schuppan,et al.  Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal , 2017, Gut.

[5]  Brad J. Wood,et al.  Simtuzumab treatment of advanced liver fibrosis in HIV and HCV‐infected adults: results of a 6‐month open‐label safety trial , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[6]  G. Targher,et al.  Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[7]  E. Bugianesi,et al.  Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease , 2016, PloS one.

[8]  K. Nakao,et al.  Lipotoxicity pathways intersect in hepatocytes: Endoplasmic reticulum stress, c‐Jun N‐terminal kinase‐1, and death receptors , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  Dermot F. Reilly,et al.  The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. , 2016, Gastroenterology.

[10]  H. Yki-Järvinen,et al.  Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD—A Systematic Review , 2016, International journal of molecular sciences.

[11]  O. Ilkayeva,et al.  Integrated Regulation of Hepatic Lipid and Glucose Metabolism by Adipose Triacylglycerol Lipase and FoxO Proteins. , 2016, Cell reports.

[12]  S. Bellentani,et al.  A "systems medicine" approach to the study of non-alcoholic fatty liver disease. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[13]  Luca Valenti,et al.  The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target? , 2016, Expert review of gastroenterology & hepatology.

[14]  Ji Luo,et al.  NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis , 2016, Nature.

[15]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[16]  S. Romeo,et al.  Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis , 2015, BioMed research international.

[17]  Mary E Rinella,et al.  Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.

[18]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[19]  Y. Kido,et al.  Pathogenesis of Selective Insulin Resistance in Isolated Hepatocytes* , 2015, The Journal of Biological Chemistry.

[20]  C. Trautwein,et al.  Hepatic fibrosis: Concept to treatment. , 2015, Journal of hepatology.

[21]  G. Alexander,et al.  Selective insulin resistance in hepatocyte senescence. , 2015, Experimental cell research.

[22]  K. Cusi,et al.  The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease , 2015, Hepatology.

[23]  V. Ratziu,et al.  Pharmacological agents for NASH , 2013, Nature Reviews Gastroenterology &Hepatology.

[24]  A. Lonardo,et al.  From NAFLD in clinical practice to answers from guidelines. , 2013, Journal of hepatology.

[25]  L. N. Valenti,et al.  Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects , 2013, International Journal of Obesity.

[26]  S. Friedman,et al.  Mechanisms of hepatic fibrogenesis. , 2011, Best practice & research. Clinical gastroenterology.

[27]  A. Dejean,et al.  Highly specialized role of Forkhead box O transcription factors in the immune system. , 2011, Antioxidants & redox signaling.

[28]  T. Libermann,et al.  Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells , 2011, Hepatology.

[29]  C. Wai,et al.  Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment , 2010, Nature Medicine.

[30]  L. N. Valenti,et al.  Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease , 2010, Gut.

[31]  F. Marra,et al.  Adipokines in liver diseases , 2009, Hepatology.

[32]  S. Caldwell,et al.  Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. , 2009, Journal of hepatology.

[33]  L. N. Valenti,et al.  Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes , 2008, Hepatology.

[34]  R. Green,et al.  Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet , 2008 .

[35]  E. Van Obberghen,et al.  Nuclear forkhead box O1 controls and integrates key signaling pathways in hepatocytes. , 2007, Endocrinology.

[36]  D. Brenner,et al.  The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells. , 2007, Gastroenterology.

[37]  R. Goldin,et al.  Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research , 2006, International journal of experimental pathology.

[38]  Y. Baruch,et al.  Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. , 2005, Journal of hepatology.

[39]  D. Accili,et al.  Transgenic rescue of insulin receptor-deficient mice. , 2004, The Journal of clinical investigation.

[40]  D. Accili,et al.  FoxOs at the Crossroads of Cellular Metabolism, Differentiation, and Transformation , 2004, Cell.

[41]  D. Accili,et al.  In Vivo Mutagenesis of the Insulin Receptor* , 2003, Journal of Biological Chemistry.

[42]  R. Fisher,et al.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.

[43]  D. Accili,et al.  Regulation of insulin action and pancreatic β-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1 , 2002, Nature Genetics.

[44]  Á. Valverde,et al.  Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. , 2011, Journal of hepatology.

[45]  R. Witek,et al.  Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. , 2009, Gastroenterology.

[46]  Mark D. Johnson,et al.  Early neonatal death in mice homozygous for a null allele of the insulin receptor gene , 1996, Nature Genetics.